| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:3674-3679.)
© 2004 American Heart Association, Inc.
Heart Failure |
From the Department of Internal Medicine, National Cardiovascular Center, Osaka (N.N., J.M., Y.Y., F.O., W.S., M.K., K.M.); Cardiovascular Division, Kansai Rosai Hospital, Hyogo (M.U.); and Departments of Pharmacy (K.U.) and Biochemistry (K.K.), National Cardiovascular Center Research Institute, Osaka, Japan.
Reprint requests to Noritoshi Nagaya, MD, Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. E-mail nagayann{at}hsp.ncvc.go.jp
Received April 30, 2004; revision received July 6, 2004; accepted August 23, 2004.
Background Ghrelin is a novel growth hormonereleasing peptide that also induces vasodilation, inhibits sympathetic nerve activity, and stimulates feeding through growth hormoneindependent mechanisms. We investigated the effects of ghrelin on left ventricular (LV) function, exercise capacity, and muscle wasting in patients with chronic heart failure (CHF).
Methods and Results Human synthetic ghrelin (2 µg/kg twice a day) was intravenously administered to 10 patients with CHF for 3 weeks. Echocardiography, cardiopulmonary exercise testing, dual x-ray absorptiometry, and blood sampling were performed before and after ghrelin therapy. A single administration of ghrelin elicited a marked increase in serum GH (25-fold). Three-week administration of ghrelin resulted in a significant decrease in plasma norepinephrine (1132±188 to 655±134 pg/mL; P<0.001). Ghrelin increased LV ejection fraction (27±2% to 31±2%; P<0.05) in association with an increase in LV mass and a decrease in LV end-systolic volume. Treatment with ghrelin increased peak workload and peak oxygen consumption during exercise. Ghrelin improved muscle wasting, as indicated by increases in muscle strength and lean body mass. These parameters remained unchanged in 8 patients with CHF who did not receive ghrelin therapy.
Conclusions These preliminary results suggest that repeated administration of ghrelin improves LV function, exercise capacity, and muscle wasting in patients with CHF.
Key Words: growth substances heart failure hormones nutrition
This article has been cited by other articles:
![]() |
L. H. Lund, J. J. Williams, P. Freda, J. J. LaManca, T. H. LeJemtel, and D. M. Mancini Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation Eur J Heart Fail, August 1, 2009; 11(8): 789 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ashrafian, C. W. le Roux, A. Darzi, and T. Athanasiou Effects of Bariatric Surgery on Cardiovascular Function Circulation, November 11, 2008; 118(20): 2091 - 2102. [Full Text] [PDF] |
||||
![]() |
A. Laviano, A. Inui, D. L. Marks, M. M. Meguid, C. Pichard, F. Rossi Fanelli, and M. Seelaender Neural control of the anorexia-cachexia syndrome Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1000 - E1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, B. Sook Jhun, C. Hoon Ha, and Z.-G. Jin Molecular Mechanisms of Ghrelin-Mediated Endothelial Nitric Oxide Synthase Activation Endocrinology, August 1, 2008; 149(8): 4183 - 4192. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ariyasu, H. Iwakura, G. Yamada, K. Nakao, K. Kangawa, and T. Akamizu Efficacy of Ghrelin as a Therapeutic Approach for Age-Related Physiological Changes Endocrinology, July 1, 2008; 149(7): 3722 - 3728. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Strassburg, S. D. Anker, T. R. Castaneda, L. Burget, D. Perez-Tilve, P. T. Pfluger, R. Nogueiras, H. Halem, J. Z. Dong, M. D. Culler, et al. Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E78 - E84. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yukawa, D. S. Weigle, C. D. Davis, B. T. Marck, and T. Wolden-Hanson Peripheral ghrelin treatment stabilizes body weights of senescent male Brown Norway rats at baseline and after surgery Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1453 - R1460. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Akamizu, H. Iwakura, H. Ariyasu, H. Hosoda, T. Murayama, M. Yokode, S. Teramukai, H. Seno, T. Chiba, S. Noma, et al. Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite. Eur. J. Endocrinol., April 1, 2008; 158(4): 491 - 498. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. DeBoer, X. Zhu, P. R. Levasseur, A. Inui, Z. Hu, G. Han, W. E. Mitch, J. E. Taylor, H. A. Halem, J. Z. Dong, et al. Ghrelin Treatment of Chronic Kidney Disease: Improvements in Lean Body Mass and Cytokine Profile Endocrinology, February 1, 2008; 149(2): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. B. Chaudhri, K. Wynne, and S. R. Bloom Can Gut Hormones Control Appetite and Prevent Obesity? Diabetes Care, February 1, 2008; 31(Supplement_2): S284 - S289. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. O. Schwenke, T. Tokudome, M. Shirai, H. Hosoda, T. Horio, I. Kishimoto, and K. Kangawa Exogenous Ghrelin Attenuates the Progression of Chronic Hypoxia-Induced Pulmonary Hypertension in Conscious Rats Endocrinology, January 1, 2008; 149(1): 237 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wu, M. Zhou, P. Das, W. Dong, Y. Ji, D. Yang, M. Miksa, F. Zhang, T. S. Ravikumar, and P. Wang Ghrelin inhibits sympathetic nervous activity in sepsis Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1697 - E1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, J. Pang, H. Yin, M. Li, W. Hao, C. Chen, and J.-M. Cao Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2952 - H2958. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Vestergaard, N. H. Andersen, T. K. Hansen, L. M. Rasmussen, N. Moller, K. E. Sorensen, E. Sloth, and J. O. L. Jorgensen Cardiovascular effects of intravenous ghrelin infusion in healthy young men Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3020 - H3026. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Piccoli, L. Degen, C. MacLean, S. Peter, L. Baselgia, F. Larsen, C. Beglinger, and J. Drewe Pharmacokinetics and Pharmacodynamic Effects of an Oral Ghrelin Agonist in Healthy Subjects J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1814 - 1820. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. von Haehling, W. Doehner, and S. D Anker Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res, January 15, 2007; 73(2): 298 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Carlson and D. E. Cummings Prospects for an anti-ghrelin vaccine to treat obesity. Mol. Interv., October 1, 2006; 6(5): 249 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Bertoli, P Magni, V Krogh, M Ruscica, E Dozio, G Testolin, and A Battezzati Is ghrelin a signal of decreased fat-free mass in elderly subjects? Eur. J. Endocrinol., August 1, 2006; 155(2): 321 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Chaudhri, C. Small, and S. Bloom Gastrointestinal hormones regulating appetite Phil Trans R Soc B, July 29, 2006; 361(1471): 1187 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. D. Dixit, A. T. Weeraratna, H. Yang, D. Bertak, A. Cooper-Jenkins, G. J. Riggins, C. G. Eberhart, and D. D. Taub Ghrelin and the Growth Hormone Secretagogue Receptor Constitute a Novel Autocrine Pathway in Astrocytoma Motility J. Biol. Chem., June 16, 2006; 281(24): 16681 - 16690. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tesauro, F. Schinzari, M. Iantorno, S. Rizza, D. Melina, D. Lauro, and C. Cardillo Ghrelin Improves Endothelial Function in Patients With Metabolic Syndrome Circulation, November 8, 2005; 112(19): 2986 - 2992. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagaya, T. Itoh, S. Murakami, H. Oya, M. Uematsu, K. Miyatake, and K. Kangawa Treatment of Cachexia With Ghrelin in Patients With COPD Chest, September 1, 2005; 128(3): 1187 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Moran, N. D. Luscombe-Marsh, M. Noakes, G. A. Wittert, J. B. Keogh, and P. M. Clifton The Satiating Effect of Dietary Protein Is Unrelated to Postprandial Ghrelin Secretion J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5205 - 5211. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |